1319 related articles for article (PubMed ID: 33524041)
1. Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab.
Meoni G; Ghini V; Maggi L; Vignoli A; Mazzoni A; Salvati L; Capone M; Vanni A; Tenori L; Fontanari P; Lavorini F; Peris A; Bartoloni A; Liotta F; Cosmi L; Luchinat C; Annunziato F; Turano P
PLoS Pathog; 2021 Feb; 17(2):e1009243. PubMed ID: 33524041
[TBL] [Abstract][Full Text] [Related]
2. Integrative Plasma Metabolic and Lipidomic Modelling of SARS-CoV-2 Infection in Relation to Clinical Severity and Early Mortality Prediction.
Lodge S; Lawler NG; Gray N; Masuda R; Nitschke P; Whiley L; Bong SH; Yeap BB; Dwivedi G; Spraul M; Schaefer H; Gil-Redondo R; Embade N; Millet O; Holmes E; Wist J; Nicholson JK
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511373
[TBL] [Abstract][Full Text] [Related]
3. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers.
Danlos FX; Grajeda-Iglesias C; Durand S; Sauvat A; Roumier M; Cantin D; Colomba E; Rohmer J; Pommeret F; Baciarello G; Willekens C; Vasse M; Griscelli F; Fahrner JE; Goubet AG; Dubuisson A; Derosa L; Nirmalathasan N; Bredel D; Mouraud S; Pradon C; Stoclin A; Rozenberg F; Duchemin J; Jourdi G; Ellouze S; Levavasseur F; Albigès L; Soria JC; Barlesi F; Solary E; André F; Pène F; Ackerman F; Mouthon L; Zitvogel L; Marabelle A; Michot JM; Fontenay M; Kroemer G
Cell Death Dis; 2021 Mar; 12(3):258. PubMed ID: 33707411
[TBL] [Abstract][Full Text] [Related]
4. Lipidomic alteration of plasma in cured COVID-19 patients using ultra high-performance liquid chromatography with high-resolution mass spectrometry.
Bai Y; Huang W; Li Y; Lai C; Huang S; Wang G; He Y; Hu L; Chen C
Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33635316
[TBL] [Abstract][Full Text] [Related]
5. Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients.
Sabbatinelli J; Giuliani A; Matacchione G; Latini S; Laprovitera N; Pomponio G; Ferrarini A; Svegliati Baroni S; Pavani M; Moretti M; Gabrielli A; Procopio AD; Ferracin M; Bonafè M; Olivieri F
Mech Ageing Dev; 2021 Jan; 193():111413. PubMed ID: 33307107
[TBL] [Abstract][Full Text] [Related]
6. Uneven metabolic and lipidomic profiles in recovered COVID-19 patients as investigated by plasma NMR metabolomics.
Bizkarguenaga M; Bruzzone C; Gil-Redondo R; SanJuan I; Martin-Ruiz I; Barriales D; Palacios A; Pasco ST; González-Valle B; Laín A; Herrera L; Azkarate A; Vesga MA; Eguizabal C; Anguita J; Embade N; Mato JM; Millet O
NMR Biomed; 2022 Feb; 35(2):e4637. PubMed ID: 34708437
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.
Innes AJ; Cook LB; Marks S; Bataillard E; Crossette-Thambiah C; Sivasubramaniam G; Apperley J; Milojkovic D
Br J Haematol; 2020 Aug; 190(4):e198-e200. PubMed ID: 32593183
[No Abstract] [Full Text] [Related]
8. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C;
J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677
[TBL] [Abstract][Full Text] [Related]
11. A lipidomic view of SARS-CoV-2.
Ebrahimi KH; McCullagh JSO
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34313294
[TBL] [Abstract][Full Text] [Related]
12. A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.
Khiali S; Khani E; Entezari-Maleki T
J Clin Pharmacol; 2020 Sep; 60(9):1131-1146. PubMed ID: 32557541
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
Kyriakopoulos C; Ntritsos G; Gogali A; Milionis H; Evangelou E; Kostikas K
Respirology; 2021 Nov; 26(11):1027-1040. PubMed ID: 34605114
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab: From Rheumatic Diseases to COVID-19.
Raiteri A; Piscaglia F; Granito A; Tovoli F
Curr Pharm Des; 2021; 27(13):1597-1607. PubMed ID: 33719967
[TBL] [Abstract][Full Text] [Related]
16. Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study.
Moes DJAR; van Westerloo DJ; Arend SM; Swen JJ; de Vries A; Guchelaar HJ; Joosten SA; de Boer MGJ; van Gelder T; van Paassen J
Clin Pharmacokinet; 2022 Feb; 61(2):231-247. PubMed ID: 34633645
[TBL] [Abstract][Full Text] [Related]
17. The effect of tocilizumab on severe COVID-19 infection: Review of current evidence.
Yakar Hİ; Pazarlı AC; İnönü Köseoğlu H; Kanbay A
Tuberk Toraks; 2021 Mar; 69(1):74-83. PubMed ID: 33853308
[TBL] [Abstract][Full Text] [Related]
18. Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.
Masuccio FG; Lo Re M; Bertolotto A; Capobianco M; Solaro C
Mult Scler Relat Disord; 2020 Nov; 46():102592. PubMed ID: 33296987
[TBL] [Abstract][Full Text] [Related]
19. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
Galván-Román JM; Rodríguez-García SC; Roy-Vallejo E; Marcos-Jiménez A; Sánchez-Alonso S; Fernández-Díaz C; Alcaraz-Serna A; Mateu-Albero T; Rodríguez-Cortes P; Sánchez-Cerrillo I; Esparcia L; Martínez-Fleta P; López-Sanz C; Gabrie L; Del Campo Guerola L; Suárez-Fernández C; Ancochea J; Canabal A; Albert P; Rodríguez-Serrano DA; Aguilar JM; Del Arco C; de Los Santos I; García-Fraile L; de la Cámara R; Serra JM; Ramírez E; Alonso T; Landete P; Soriano JB; Martín-Gayo E; Fraile Torres A; Zurita Cruz ND; García-Vicuña R; Cardeñoso L; Sánchez-Madrid F; Alfranca A; Muñoz-Calleja C; González-Álvaro I;
J Allergy Clin Immunol; 2021 Jan; 147(1):72-80.e8. PubMed ID: 33010257
[TBL] [Abstract][Full Text] [Related]
20. Special case of a patient in the blast phase of chronic myeloid leukemia successfully treated with tocilizumab during critical SARS-CoV-2 infection.
Bouchlarhem A; Es-Saad O; Haddar L; Lamzouri O; Elaidouni G; Mimouni H; Bkiyar H; Housni B
J Int Med Res; 2022 Mar; 50(3):3000605221082875. PubMed ID: 35301903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
